203 related articles for article (PubMed ID: 35800054)
1. PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
Liu Y; Xiang J; Peng G; Shen C
Front Oncol; 2022; 12():620190. PubMed ID: 35800054
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
Front Oncol; 2020; 10():1409. PubMed ID: 32974146
[TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma.
Zhou Y; Xu M; Zhao K; Liu B
J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576
[TBL] [Abstract][Full Text] [Related]
5. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer.
Bi F; Chen Y; Yang Q
Cancer Cell Int; 2020; 20():373. PubMed ID: 32774167
[TBL] [Abstract][Full Text] [Related]
6. Tumor mutational burden is associated with poor outcomes in diffuse glioma.
Wang L; Ge J; Lan Y; Shi Y; Luo Y; Tan Y; Liang M; Deng S; Zhang X; Wang W; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Mar; 20(1):213. PubMed ID: 32164609
[TBL] [Abstract][Full Text] [Related]
7. A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas.
Zhang Y; Yu B; Tian Y; Ren P; Lyu B; Fu L; Chen H; Li J; Gong S
Front Genet; 2022; 13():957059. PubMed ID: 36246611
[No Abstract] [Full Text] [Related]
8. Identification of Iron Metabolism-Related Genes as Prognostic Indicators for Lower-Grade Glioma.
Xu S; Wang Z; Ye J; Mei S; Zhang J
Front Oncol; 2021; 11():729103. PubMed ID: 34568059
[TBL] [Abstract][Full Text] [Related]
9. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
Zhang C; Li Z; Qi F; Hu X; Luo J
Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis of the disulfidptosis-related gene
Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
[TBL] [Abstract][Full Text] [Related]
11. A prognostic NAD+ metabolism-related gene signature for predicting response to immune checkpoint inhibitor in glioma.
Jiang C; Zhou Y; Yan L; Zheng J; Wang X; Li J; Jiang X
Front Oncol; 2023; 13():1051641. PubMed ID: 36845744
[TBL] [Abstract][Full Text] [Related]
12. High expression of PCOLCE gene indicate poor prognosis in patients and are associated with immune infiltration in glioma.
Guo Q; Gao X; Li J; Liu Y; Liu J; Yang H; Cui M; Zhang M; Duan L; Ma X
Sci Rep; 2023 Mar; 13(1):3820. PubMed ID: 36882457
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
15. A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients.
Xiang Z; Chen X; Lv Q; Peng X
Front Genet; 2021; 12():697819. PubMed ID: 34408772
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
17. Tumor Mutation Burden-Related Histopathologic Features for Predicting Overall Survival in Gliomas Using Graph Deep Learning.
Sun C; Luo T; Liu Z; Ge J; Shao L; Liu X; Li B; Zhang S; Qiu Q; Wei W; Wang S; Bian XW; Tian J
Am J Pathol; 2023 Dec; 193(12):2111-2121. PubMed ID: 37741452
[TBL] [Abstract][Full Text] [Related]
18. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
19. A Prognostic Microenvironment-Related Immune Signature
Qiu H; Li Y; Cheng S; Li J; He C; Li J
Front Oncol; 2020; 10():580263. PubMed ID: 33425732
[TBL] [Abstract][Full Text] [Related]
20. A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with
Fu J; Li Y; Li C; Tong Y; Li M; Cang S
Transl Cancer Res; 2021 Sep; 10(9):3963-3978. PubMed ID: 35116695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
